Business
Half-year Report
Solvonis Therapeutics PLC announced its unaudited interim results for the six months ending June 30, 2025. The company's cash and cash equivalents at the period's end totaled £1,719,000, a significant increase from £27,000 in H1 2024. The loss before taxation for the period was £1,621,000, compared to £469,000 in the previous year. The Group's net assets at the period-end were £6,935,000, up from £3,084,000 at the end of 2024, while total assets reached £9,545,000, increasing from £3,203,000 at the end of the prior year. The company completed the acquisition of Awakn Life Sciences, recording an intangible asset of £5,609,237 related to the acquisition. Subsequent to the period end, Solvonis raised £1 million through an equity fundraise. Disclaimer*
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n30 September 2025\nSolvonis Therapeutics PLC\nUnaudited interim results for the six months to 30 June 2025\nSolvonis Therapeutics Plc (the \"Company\" or \"Solvonis\"), an innovative biotechnology company focused on co-developing therapeutics for mental health disorders, announces its unaudited interim results for the six months to 30 June 2025.\n \nChairman's Statement\nThe first half of 2025 has been a period of significant progress for Solvonis. Most notably, we completed the acquisition of Awakn Life Sciences, a transformational step that broadened our pipeline, strengthened our team, and accelerated our strategy to become a leading CNS-focused biopharmaceutical platform.\nAlongside this, we advanced our R&D programmes across addiction, neuropsychiatry, and neurology. Highlights included the continued progression of SVN-001 in Alcohol Use Disorder, preparations for the next clinical stage of SVN-002 in the US, and the advancement of our AI-discovered preclinical candidate, SVN-SDN-014, which is targeted for PTSD. Together, these programmes represent a balanced portfolio spanning late-, mid- and early-stage development.\nOur focus remains firmly on executing this strategy: delivering clinical and regulatory milestones across our lead programmes, strengthening our discovery engine, and positioning Solvonis as a credible partner of choice for large pharma in CNS disorders. With the Awakn integration well underway and our discovery platform gaining momentum, the Board believes the Company is well placed to deliver material value for patients and shareholders alike.\nKey Financial Indicators\n \n· Cash and cash equivalents at period end were £1,719,000 (H1 2024: £27,000)\n· Loss before taxation for the period was £1,621,000 (H1 2024: £469,000)\n· The Group held net assets at period-end of £6,935,000 (31 December 2024: £3,084,000)\n· The Group held total assets at period-end of £9,545,000 (31 December 2024: £3,203,000)\n \nRisk factors\nThe principal risks facing the Group remain broadly consistent with those set out in our 2024 Annual Report. While certain risk factors have evolved following the acquisition of Awakn Life Sciences, there have been no material changes. Shareholders are directed to the risk disclosures contained in the pro...